Do Today’s Results Make GlaxoSmithKline plc A Contrarian Buy?

Roland Head explains why after a disappointing 2015, GlaxoSmithKline plc (LON:GSK) may now be poised to deliver real growth.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in GlaxoSmithKline (LSE: GSK) have risen modestly so far this afternoon, despite the company reporting a 21% fall in core earnings for 2015.

City investors were pleased because Glaxo’s full-year results, which were published at noon on Wednesday, were exactly in line with forecasts. Revenue of £23.9bn was up 4% on the year, while earnings per share of 75.7p matched up with forecasts for earnings of 75.9p per share.

Although there were declines in various areas, these appear to be stabilising and were as expected. The whole picture is one of a company that should be able to fulfil its promise of returning to growth in 2016.

Shares in Glaxo have trended lower since mid-2013. The firm has had to cope with a sharp decline in sales of key respiratory products and a major restructuring. Glaxo stock is worth around 15% less than when it peaked in May 2013, but the firm has been able to protect its dividend.

Dividend strength?

Today, Glaxo confirmed an ordinary dividend of 80p for 2015, plus a special dividend of 20p. This will be paid alongside the final dividend in April and will mean that shareholders have received a trailing yield of 6.9% this year. That’s a decent compensation for the firm’s lacklustre share price performance, in my view.

Glaxo confirmed today that it expects to pay a dividend of 80p in both 2016 and 2017. While growth isn’t on the cards, I can live with a flat payout for a couple of years if the firm’s turnaround continues to plan.

Today’s figures suggest that the underlying performance of the business remains strong. Glaxo’s core operating profit margin was 23.9%. The profits from the sale of the Oncology business were used to reduce net debt from £14.4bn to £10.7bn. This should cut finance costs going forward and strengthens the firm’s balance sheet.

New products = new sales

Although Glaxo has suffered from falling sales of its ex-patent product Advair, the group does have a pipeline of new products which are now starting to feed through to sales.

£2bn of new product sales were reported for last year, driven mainly by Glaxo’s HIV business and its respiratory division. New product sales are now expected to hit the group’s target level of £6bn in 2018, two years ahead of the original 2020 target date.

Outlook improving

In May 2015, Glaxo told investors that it hopes to achieve mid-to-high single digit annual growth in core earnings per share between 2016 and 2020, excluding exchange rate movements.

Today’s results give me confidence that this target is reasonable. Indeed, the firm may manage to beat its own targets. In its guidance for 2016, Glaxo said that it hopes to achieve double-digit earnings per share growth, on a constant exchange rate basis.

This ties in with the latest analysts’ forecasts, which suggest that Glaxo’s core earnings per share could rise by 11% to 84.4p in 2016. This puts the firm’s stock on a forecast P/E of 16.9 with a prospective yield of 5.5%.

This looks attractive to me, and I recently added more Glaxo shares to my portfolio. I rate the stock as a strong long-term income buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »